



## **Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval**

March 28, 2017

TARRYTOWN, N.Y. and PARIS, March 28, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will hold a conference call for the financial community to discuss the U.S. Food and Drug Administration approval of DUPIXENT® (dupilumab). The conference call will take place today, March 28, 2017, at 4pm ET/10pm CEST.

The conference call will include a presentation followed by a Q&A session and will be accessible through an audio webcast at [www.regeneron.com](http://www.regeneron.com) and [www.sanofi.com](http://www.sanofi.com), and also via the following telephone numbers:

U.S.: +1 (888) 660 6127  
France: +33 (0) 8 00 90 93 22  
UK: +44 (0) 800 028 8438  
International: +1 (973) 890 8355  
Access code: 92138426

A replay of the conference call and webcast will be archived on the Companies' websites.

### **About Regeneron Pharmaceuticals, Inc.**

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, atopic dermatitis and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit [www.regeneron.com](http://www.regeneron.com) or follow @Regeneron on Twitter.

### **About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

#### **Contacts Regeneron:**

##### **Media Relations**

**Ilana Tabak**

Tel: + 1 (914) 847-3836

Mobile: +1 (914) 450-6677

[ilana.tabak@regeneron.com](mailto:ilana.tabak@regeneron.com)

##### **Investor Relations**

**Manisha Narasimhan, Ph.D.**

Tel: +1 (914) 847-5126

[Manisha.narasimhan@regeneron.com](mailto:Manisha.narasimhan@regeneron.com)

#### **Contacts Sanofi:**

##### **Media Relations**

**Ashleigh Koss**

Tel: 908-981-8745

[ashleigh.koss@sanofi.com](mailto:ashleigh.koss@sanofi.com)

##### **Investor Relations**

**George Grofik**

Tel: +33 (0) 1 53 77 94 69

[ir@sanofi.com](mailto:ir@sanofi.com)

#### **U.S. Communications**

**Carrie Brown**

Tel: +1 (908) 981-6486

Mobile: +1 (908) 247-6006

[Carrie.Brown@sanofi.com](mailto:Carrie.Brown@sanofi.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approval-300430522.html>

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media